Skip to main content
Emcure Pharmaceuticals Limited logo

Emcure Pharmaceuticals Limited — Investor Relations & Filings

Ticker · EMCURE ISIN · INE168P01015 LEI · 335800WYB6OIBY9EOZ42 BSE.NS Manufacturing
Open in API
Filings indexed 201 across all filing types
Latest filing 2026-05-08 Environmental & Social …
Country IN India
Listing BSE.NS EMCURE

About Emcure Pharmaceuticals Limited

https://www.emcure.com

Emcure Pharmaceuticals Limited is a research-driven global pharmaceutical organization engaged in the development, manufacturing, and marketing of a broad range of differentiated pharmaceutical products. The company maintains a diverse portfolio across several key therapeutic areas, including gynaecology, cardiovascular, oncology, anti-infectives, and HIV/AIDS. With a strong emphasis on research and development, Emcure operates multiple state-of-the-art manufacturing facilities and R&D centers globally. Its business model focuses on complex generics and innovative formulations, serving healthcare needs in over 70 countries. The company is recognized for its vertically integrated operations and commitment to high-quality standards, catering to both regulated and emerging markets worldwide.

Recent filings

Filing Released Lang Actions
General Updates
Environmental & Social Information Classification · 90% confidence The document is an intimation letter addressed to stock exchanges regarding the ESG rating assigned to the company for the financial year 2024-25. It references SEBI regulations and discloses the ESG rating score. The document is short (1761 characters) and serves as a notification of ESG rating information rather than a detailed ESG report. Therefore, it fits best under Environmental & Social Information (SR) category, which covers reports detailing the company's performance on ESG factors.
2026-05-08 English
Copy of Newspaper Publication
Earnings Release Classification · 95% confidence The document is a newspaper publication of audited financial results for the quarter and year ended March 31, 2026. It includes extracts of consolidated and standalone financial results with key financial metrics such as total revenue, net profit before and after tax, comprehensive income, equity share capital, and earnings per share. The document references Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates the publication of financial results in newspapers. The document is an extract and summary of the financial results, not the full detailed report itself. It is a public announcement of the audited financial results rather than the full Annual Report or Interim Report. The length is 7418 characters, which is relatively short and consistent with an announcement or extract rather than a full report. Therefore, this document fits best as an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results with key highlights only. FY 2026
2026-05-06 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the availability of the audio recording of the company's Q4 FY26 earnings call. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provides a link to the audio file of the earnings call. The document does not contain the transcript or financial data itself, but rather announces the availability of the audio recording. The document length is short (1454 characters), and it serves as an announcement rather than the full transcript or report. Therefore, the appropriate classification is Call Transcript (CT), as it relates directly to the earnings call audio recording, which is a form of call transcript material, even though it is an audio recording announcement. However, since it only announces the availability of the audio recording and does not contain the transcript text, it is best classified as Regulatory Filings (RNS) because it is a regulatory announcement about the earnings call audio recording availability, not the transcript itself or the earnings release report.
2026-05-05 English
Change in Management
Board/Management Information Classification · 100% confidence The document is an official communication addressed to stock exchanges regarding the re-appointment of two directors of the company, Emcure Pharmaceuticals Limited. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosures about changes in directors or key managerial personnel. The content includes details about the re-appointment dates, brief profiles of the directors, and their relationships with other directors. There is no financial data, earnings information, or report publication mentioned. The document is clearly about board/management changes, specifically re-appointments of directors, which fits the category of Board/Management Information (MANG). The document length (6558 characters) and detailed disclosure further support this classification rather than a brief announcement or regulatory filing.
2026-05-05 English
Change in Management
Board/Management Information Classification · 95% confidence The document is an official communication addressed to stock exchanges regarding the re-appointment of two directors of Emcure Pharmaceuticals Limited. It references Regulation 30 of the SEBI Listing Regulations, which pertains to disclosures about changes in the board of directors or senior management. The content includes details about the re-appointment dates, brief profiles, and relationships of the directors. There is no financial data, earnings information, or report publication mentioned. The document is a formal announcement of changes in the company's board of directors, fitting the category of Board/Management Information (MANG). The document length (6364 characters) supports it being a detailed announcement rather than a brief notice or certification. Therefore, the appropriate classification is MANG with high confidence.
2026-05-05 English
Investor Presentation
Interim / Quarterly Report Classification · 95% confidence The document is a detailed presentation dated May 5, 2026, containing audited consolidated and standalone financial results for the quarter and year ended March 31, 2026. It includes extensive financial data such as revenue, EBITDA, PAT, segment revenue mix, and business performance highlights. The document is over 10,000 characters long and contains substantive financial data and analysis, not merely an announcement or a certification. The presence of detailed quarterly and full-year financial results with commentary and forward-looking statements aligns with the characteristics of an Interim / Quarterly Report (IR). Although it is called a 'presentation,' the depth and breadth of financial information and analysis indicate it is a comprehensive quarterly and annual financial report rather than a simple investor presentation or earnings release. Therefore, the most appropriate classification is Interim / Quarterly Report (IR). FY 2026
2026-05-05 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.